Purpose Of Review: The aim of this review is to aid in choosing safe options when assessing potential risks of acute migraine treatments based on known mechanisms of action and anticipated safety concerns.
Recent Findings: Part 1 highlights safety issues associated with commonly used medications to treat acute migraine attacks. Strategies to mitigate cardiovascular and gastrointestinal risks of nonsteroidal anti-inflammatory drugs, evaluation of cardiovascular risks of triptan and ergot alkaloids, and precautions with use of antiemetics and the novel drugs gepants and ditans are discussed to help practitioners in clinical decision-making. When available, we included recommendations from professional societies and data from pharmacovigilance systems. While guidelines on efficacy are available, one must also consider the possible risks and adverse effects of a drug when creating treatment plans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11916-022-01057-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transient destabilization of interhemispheric functional connectivity induced by spreading depolarization.
Netw Neurosci
December 2024
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
Cortical spreading depolarization (CSD), a slowly propagating wave of transient cellular depolarization, is a reliable cortical response to various brain insults (stroke, trauma, seizures) and underlying mechanism of migraine aura. Little is known about CSD effects on brain network activity. Using undirected (mutual information, MI) and directed (transfer entropy, TE) measures, we studied the dynamics of cross-hemispheric connectivity associated with the development of unilateral CSD in freely behaving rats and the involvement of inhibitory transmission in mechanisms of the coupling changes.
View Article and Find Full Text PDFEpidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022.
J Headache Pain
December 2024
Pfizer SAS, Bogota, Colombia.
Background: To describe the epidemiology and clinical characteristics of migraine and the status of treatment in Colombia. Additionally, the use of health resources by patients was measured.
Methods: This was a non-interventional, retrospective, descriptive study conducted in one Colombian Health Management Organization (HMO) from 2018 to 2022 with a follow-up period of 5 years.
Seasonal Variations in Triptan Prescription in Japan: A Nationwide Time-Series Analysis.
Brain Behav
December 2024
Department of Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan.
Objective: This study aimed to investigate seasonal differences in migraine onset in Japan and associated trends in the prescription of triptan.
Background: The relationship between seasonal changes and the onset of migraine remains largely unknown.
Methods: We combined the large-scale medical claims data in Japan with city-level meteorological data presented by the Japan Weather Association.
The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study.
Neurol Ther
December 2024
Eli Lilly Japan K.K., Kobe, Japan.
Introduction: The impact of migraine on patients' lives, including challenges they face before getting access to appropriate medical management, is not well understood. The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE [OVERCOME (Japan)] 2nd study was conducted to provide information regarding burden and experience with migraine throughout the life course.
Methods: This cross-sectional, population-based, nationwide online survey was conducted in adults with or without migraine.
Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database.
PLoS One
December 2024
Internal Medicine, Hospital, and Antiviral Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
The real-world treatment patterns at medical facilities and their physicians' specialties treating migraine have not been fully investigated in Japan. Therefore, a retrospective cohort study aimed to describe real-world clinical practice and treatment patterns in Japanese patients with migraine according to medical facilities and physicians' specialties. Anonymized claims data of patients with migraine was obtained from JMDC Inc (January 2018-June 2023).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!